A Double-Blind Comparison of Moxonidine and Atenolol in the Management of Patients with Mild-to-Moderate Hypertension

Prichard, B. N. C.; Simmons, Robert L.; Rooks, M; Haworth, Duncan; Laws, David; Wonnacott, Susan

doi:10.1097/00005344-199220004-00010

Cited by 22 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 The centrally active imidazoline receptor agonist moxonidine is a sympatholytic drug that effectively lowers blood pressure, [16][17][18][19][20] is well tolerated, and has been shown to have beneficial effects on lipid and carbohydrate metabolism and insulin sensitivity. [21][22][23] While the efficacy and safety of moxonidine has been previously documented in a postmarketing surveillance study, 24 its effect has not been previously examined in patients who were overweight and/or had the metabolic syndrome.…”

Section: Introductionmentioning

confidence: 99%

Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study

2004

View full text Add to dashboard Cite

Moxonidine is a centrally active imidazoline receptor agonist that effectively lowers blood pressure and has been shown to have beneficial effects on lipid and carbohydrate metabolism. We assessed the efficacy of moxonidine in a postmarketing surveillance study (CAMUS) conducted in 772 practices in Germany, documenting 4005 patients with hypertension, who were overweight and/or suffered from metabolic syndrome. Patients were treated with moxonidine (Cynt s ) for the first time following the baseline visit for 8 weeks. Mean blood pressure decreased from 168/97 to 141/83 mmHg for all patients and from 168/96 to 141/83 mmHg for patients with metabolic syndrome. Blood pressure reduction was particularly pronounced in patients with severe hypertension at baseline. The response rate (DBPp90 mmHg or reduction X10 mmHg) of antihypertensive treatment with moxonidine was 94.0% for all patients and 93.8% for patients with metabolic syndrome. The recommended targets for antihypertensive treatment of the German Diabetes Society/German Hypertension Society were reached by 30.5% of nondiabetics (goal: o140/90 mmHg) and by 3.6% of diabetics (goal: o130/80 mmHg) observed. After 8 weeks of treatment, patients achieved a mean weight loss of 1.4 kg, which was particularly pronounced in obese patients. The rate of patients receiving antihypertensive combination therapy was 81.1% for those with metabolic syndrome, and 63.3% for all other patients. Patients with metabolic syndrome were preferentially treated with ACE inhibitors and diuretics. We conclude that moxonidine effectively reduces blood pressure in patients with metabolic syndrome while simultaneously reducing body weight in obese patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study

2004

View full text Add to dashboard Cite

show abstract

“…Esse trabalho sugere que moxonidina tem incidência de efeitos adversos igual ou um pouco menor que o atenolol (21% e 26,5%, respectivamente) e uma tolerabilidade no mínimo igual a deste 33 .…”

Section: Comparações Com Outros Anti-hipertensivosunclassified

“…Em inúmeros estudos, foi demonstrada alta eficácia anti-hipertensiva da moxonidina no tratamento de pacientes com HAS essencial leve a moderada, tanto a curto quanto a longo prazos 7,10,14,17,20,33 , sem associação com alterações significativas no DC e na FC 8,10,14 . Este efeito anti-hipertensivo mostrou-se equipotente ao dos principais grupos de anti-hipertensivos, atualmente empregados no manejo terapêutico da HAS 7,10,14,17,20,33 .…”

Section: Comentáriosunclassified

“…Este efeito anti-hipertensivo mostrou-se equipotente ao dos principais grupos de anti-hipertensivos, atualmente empregados no manejo terapêutico da HAS 7,10,14,17,20,33 . Além desta eficácia semelhante, a moxonidina não apresentou efeitos adversos posturais (hipotensão postural), ao contrário do prazosin 34,35 , não provocou hipertensão rebote, diferentemente da clonidina e do atenolol 33 , e não desencadeou a taquicardia reflexa observada com o uso de nifedipina 20 . Nesses estudos comparativos, observou-se uma boa tolerabilidade à moxonidina, sendo esta superior à da clonidina 17 e à do prazosin 34 , bem como uma freqüência de efeitos adversos no mínimo semelhante à dos demais anti-hipertensivos, sendo inferior à da clonidina (provavelmente pela menor afinidade com os receptores a 2 ) 17,28 , e à da nifedipina 20 .…”

Section: Comentáriosunclassified

See 2 more Smart Citations

Moxonidina. Um novo anti-hipertensivo de ação central

Leães¹,

Rosito

1998

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

Imidazoline Receptor Agonist Drugs: A New Approach to the Treatment of Systemic Hypertension

Yu.¹,

Frishman²

1996

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The imidazoline receptors have recently been discovered to be involved in central nervous system control of blood pressure (I-1 receptor) and in neuroprotection for cerebral ischemia (I-2 receptor). A new class of central-acting antihypertensive agents has been developed, the imidazoline receptor agonists (rilmenidine and moxonidine), which control blood pressure effectively without the adverse effects of sedation and mental depression that are usually associated with central-acting antihypertensives. This new generation of central-acting antihypertensive agents are highly selective for the imidazoline receptor, while having a low affinity for alpha 2-adrenergic receptors.

show abstract

A Double-Blind Comparison of Moxonidine and Atenolol in the Management of Patients with Mild-to-Moderate Hypertension

Cited by 22 publications

References 0 publications

Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study

Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study

Moxonidina. Um novo anti-hipertensivo de ação central

Imidazoline Receptor Agonist Drugs: A New Approach to the Treatment of Systemic Hypertension

Contact Info

Product

Resources

About